Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Innate Pharma Reports Third Quarter 2026 Business and Financial Update

businesswire.com
IPHA The company reported its Q3 2026 financial update, highlighting a strengthened cash position and progress on its strategic priorities. Key upcoming events include Phase 1 data for IPH4502 and first patient dosing in a Phase 3 trial for lacutamab. The company also anticipates a readout from an AstraZeneca-led trial involving monalizumab. While the update details financial health and pipeline advancement, it doesn't provide strong indicators of immediate stock price movement.

Innate Pharma Reports Third Quarter 2026 Business and Financial Update MARSEILLE, France--( BUSINESS WIRE)--Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its financial update for the nine months ended September 30, 2026.

“As we approach year-end, our strengthened cash position enables us to work towards executing the next steps in advancing our strategic priorities,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “We look forward to presenting Phase 1 dose-escalation data from IPH4502, our differentiated Nectin-4 ADC, on November 18, while actively preparing for first patient dosing in the Phase 3 TELLOMAK-3 study of lacutamab in Q1 2027. We also look forward to the readout of the AstraZeneca-led PACIFIC-9 Phase 3 trial, which includes monalizumab and is now expected in the first half of 2027.”

1 Including short term investments (€20.6m) and non-current financial instruments (€6.0m).

Webcast and conference call will be held today at 2:00pm CET (8:00am ET)

Access to live webcast:

Click here

Participants may also join via telephone using the registration link below:

Click here

This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com.

A replay of the webcast will be available on the Company website for 90 days following the event.

Pipeline highlights

IPH4502 (Nectin-4 exatecan ADC):

Lacutamab (anti-KIR3DL2 antibody), developed in collaboration with Sobi:

Monalizumab (anti-NKG2A antibody), developed in collaboration with AstraZeneca:

Corporate update

Financial highlights for Q3 2026

Cash, cash equivalents and financial assets of the Company amounted to €96.8 million as of September 30, 2026, which includes the $75 million upfront payment resulting from the closing of the Sobi transaction and the aggregate gross proceeds from the €30 million private placement offering of ordinary shares that occurred in August 2026. Also as of September 30, 2026, financial liabilities amounted to €16.2 million.

Revenues for the first nine months of 2026 amounted to €3.4 million (€2.3 million for the same period in 2025). Revenue from collaboration and licensing agreements mainly results from the partial or entire recognition of the proceeds received pursuant to the co-development and license agreements with AstraZeneca and research collaboration and license agreements with Sanofi.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code

Ticker code

LEI

FR0010331421

Euronext: IPH Nasdaq: IPHA

9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.